Department of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), No.183 Xinqiao Main Street, Shapingba District, Chongqing, 400037, China.
BMC Neurol. 2024 Jan 12;24(1):24. doi: 10.1186/s12883-024-03527-0.
Stress hyperglycemia ratio (SHR) reflects a true acute hyperglycemic state during acute basilar artery occlusion (ABAO). We aimed to investigate the association between SHR and short-term and long-term outcomes in patients with ABAO receiving endovascular treatment (EVT).
We selected patients treated with EVT from the BASILAR study, a nationwide prospective registry. A total 250 patients with documented glucose and glycated hemoglobin (HbA1C) values at admission were included. SHR was calculated as the ratio of glucose/HbA1C. All 250 patients completed 90 days of follow-up and 234 patients (93.6%) completed 1 year of follow-up. The primary outcome was the favorable outcome defined as modified Rankin Scale (mRS) score ≤ 3 at 90 days. Safety outcomes included mortality at 90 days and 1 year, and intracranial hemorrhage.
Among the 250 patients included, patients with higher tertiles of SHR were associated with decreased odds of a favorable functional outcome at 90 days (adjusted OR, 0.26; 95% CI, 0.12-0.56; P = 0.001 and adjusted OR, 0.37; 95% CI, 0.18-0.80; P = 0.01; respectively) and 1 year (adjusted OR, 0.34; 95% CI, 0.16-0.73; P = 0.006 and adjusted OR, 0.38; 95% CI, 0.18-0.82; P = 0.01; respectively) after adjusting for confounding covariates. The mortality was comparable across tertiles of SHR groups at 90 days and 1 year.
Our study showed that SHR was associated with a decreased probability of favorable functional outcome both at 90 days and 1 year after EVT in patients with ABAO. The relationship was more pronounced in non-diabetes patients.
Clinical Trial Registry Identifier: ChiCTR1800014759 (November 12, 2013).
应激性高血糖比值(SHR)反映了急性基底动脉闭塞(ABAO)期间的真实急性高血糖状态。我们旨在研究接受血管内治疗(EVT)的 ABOA 患者的 SHR 与短期和长期结局之间的关系。
我们从全国性前瞻性登记研究 BASILAR 研究中选择接受 EVT 治疗的患者。共纳入 250 例有入院时血糖和糖化血红蛋白(HbA1C)记录的患者。SHR 计算为血糖/HbA1C 的比值。所有 250 例患者均完成了 90 天的随访,234 例(93.6%)完成了 1 年的随访。主要结局为 90 天改良Rankin 量表(mRS)评分≤3 的良好结局。安全性结局包括 90 天和 1 年的死亡率和颅内出血。
在 250 例患者中,SHR 较高的三分位患者 90 天的良好功能结局的可能性降低(调整后的比值比,0.26;95%可信区间,0.12-0.56;P=0.001 和调整后的比值比,0.37;95%可信区间,0.18-0.80;P=0.01)和 1 年(调整后的比值比,0.34;95%可信区间,0.16-0.73;P=0.006 和调整后的比值比,0.38;95%可信区间,0.18-0.82;P=0.01),调整混杂协变量后。在 90 天和 1 年时,SHR 组的死亡率在各三分位之间相当。
我们的研究表明,在 ABOA 患者接受 EVT 后 90 天和 1 年,SHR 与良好功能结局的可能性降低有关。在非糖尿病患者中,这种关系更为明显。
临床试验注册号:ChiCTR1800014759(2013 年 11 月 12 日)。